RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.
about
Diabetes, Endothelial Dysfunction, and Vascular Repair: What Should a Diabetologist Keep His Eye on?Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat.Recent achievements in the management of Raynaud's phenomenon.Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure?Discovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers.The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis.Clinical utility of valsartan in the treatment of hypertension in children and adolescentsTelmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosisBradykinin antagonist counteracts the acute effect of both angiotensin-converting enzyme inhibition and of angiotensin receptor blockade on the lower limit of autoregulation of cerebral blood flow.Brain angiotensin-converting enzyme type 2 shedding contributes to the development of neurogenic hypertension.Angiotensin Receptor Blockers Decrease the Risk of Major Adverse Cardiovascular Events in Patients with End-Stage Renal Disease on Maintenance Dialysis: A Nationwide Matched-Cohort StudyMidlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging StudyAngiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes.Small-molecule AT2 receptor agonists.The growth factor midkine regulates the renin-angiotensin system in miceLive longer sans the AT1A receptorRole of the renin-angiotensin system in autoimmune inflammation of the central nervous system.Renal dysfunction is associated with shorter telomere length in heart failure.On target to dual block RAS?Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor.Recent changes in the landscape of combination RAS blockade.Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials.Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy.Medical management and strategies to prevent coronary artery disease in patients with type 2 diabetes mellitus.Renin-angiotensin system blocking drugs.Neuropeptides: metabolism to bioactive fragments and the pharmacology of their receptors.Coronary artery bypass graft: why is the saphenous vein prone to intimal hyperplasia?Olmesartan-associated enteropathy: new insights on the natural history? Report of two cases.Recent Progress in Vascular Aging: Mechanisms and Its Role in Age-related Diseases.Possible prevention of dialysis-requiring congestive heart failure by angiotensin-II receptor blockers in non-dialysis Japanese patients with Stage 5 chronic kidney disease.Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease.Anti-necrotic and cardioprotective effects of a cytosolic renin isoform under ischemia-related conditions.Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs.Renin-angiotensin system: Meta-analyses can misdirect decisions on treatment.Altered regional blood flow distribution in Mas-deficient mice.Effects of telmisartan and pioglitazone on high fructose induced metabolic syndrome in rats.Regulation of aortic extracellular matrix synthesis via noradrenergic system and angiotensin II in juvenile rats.Early remodeling processes as predictors of diastolic function 5 years after reperfused acute myocardial infarction and intracoronary progenitor cell application
P2860
Q28082426-FC28B8E4-B89C-49D1-94FC-A73EC61BD6BCQ33674294-FED0859D-D6EB-4270-A734-6F4E693E7208Q33797622-210C9C59-9439-42A7-96B0-463ABEF27EB0Q34306932-5CFEEB08-C0E0-4768-B4C2-5535ABF1D7F2Q34543485-A4F072DD-E9B9-4141-8BBE-90E419DE7B65Q34765075-80BB18BE-EA75-4866-A555-93B0FC881F4CQ34957546-5DD7C62F-36D7-4A5A-972D-ECA5FFFFB55EQ35036184-688DF62C-09AC-42BB-8AC1-EAA1A1567DCAQ35064653-FDEB9E17-C9CD-488E-8C8E-8169D08E8F18Q35776904-201ED5FE-D1EA-4D02-AC6A-E7B42023F35AQ35816145-FF4DE676-1A3E-4592-8729-BFD62701497BQ35870513-5FE7647E-45C9-4616-A9E6-2326BA330B15Q36160619-53B6DECE-43E0-44F8-A992-AEE282601145Q36400573-D2D029D6-10C5-4524-9602-1CFCC85C057CQ37209205-0DDB0803-D5B1-4C14-AA29-2ACA51405377Q37230548-208CE6DF-F238-4FA2-99DB-0C8FDDD3E54FQ37329566-1E5D7305-84D8-48C1-A523-20C96600DF72Q37363993-8F7DE003-1DB9-4460-8D73-97CE6361F1C7Q37368669-EE326ED9-DCEA-481C-A647-B6EB1F7033D7Q37397232-646343C2-080F-4361-A9C6-734F7E923B4AQ37629835-64F5F2E3-AC9A-4BE6-83EA-98EAE5323C4AQ37907072-FD2AFCDE-4444-4438-984C-079A018C2DF7Q38052452-6D8C1EBA-0B94-4832-AF43-3AD2C7FB9BCFQ38079914-8D4BA983-33C5-4E0F-97D5-E78E839A54B5Q38137851-38207257-B814-4B72-915C-D692453D347AQ38217456-60E85692-F5F3-4D37-86B0-BA021AA7E491Q38220601-1290B3CE-98B3-45AC-B113-46606D782D36Q41042155-229979BD-3BD6-42C6-825D-DC978AC5365FQ41108769-343E3217-C329-4F1B-81FC-A56F88EDC126Q41564747-D916BDB1-9DF4-4C21-844D-91DF2FE5330BQ41663598-F4CC9877-C1FA-4F2F-AE1A-334556397142Q42480886-BFFC534E-7852-4C4B-88C8-74DC487F3F41Q43407169-90131FFE-0EAB-4A89-B6F7-4A5656545DE3Q44407942-974AA774-9F8C-49C0-B326-B487AA36B11AQ48125284-D56E0832-33C7-4FDE-8278-848E6C8DFB99Q51283845-C5CAF946-0307-432E-BDB6-9DB10EF2D780Q54298584-67516CA8-BB65-4DA6-B126-201BC8CE8217Q58816067-D3FFD267-C36A-46FC-97C3-62C93FC28E37
P2860
RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
RAS blockade with ARB and ACE ...... tionale and patient selection.
@en
RAS blockade with ARB and ACE ...... tionale and patient selection.
@nl
type
label
RAS blockade with ARB and ACE ...... tionale and patient selection.
@en
RAS blockade with ARB and ACE ...... tionale and patient selection.
@nl
prefLabel
RAS blockade with ARB and ACE ...... tionale and patient selection.
@en
RAS blockade with ARB and ACE ...... tionale and patient selection.
@nl
P2093
P2860
P1476
RAS blockade with ARB and ACE ...... tionale and patient selection.
@en
P2093
Christian Werner
Johannes Mann
Koon K Teo
Magnus Baumhäkel
Michael Böhm
Roland Schmieder
P2860
P2888
P304
P356
10.1007/S00392-008-0668-3
P577
2008-05-03T00:00:00Z